Neurocrine biosciences and voyager therapeutics enter strategic collaboration for development and commercialization of voyager's gba1 program and other next-generation gene therapies for neurological diseases

- voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-sharing in the u.s. for the gba1 program following phase 1 readout -
NBIX Ratings Summary
NBIX Quant Ranking